Cost of medical care for HIV‐infected patients within a regional population from 1997 to 2006

To report on the cost of medical care for HIV‐infected patients stratified by CD4 cell count for a regional population over a 9‐year period, and to examine the effect of reporting costs of HIV care only or only in antiretroviral therapy (ART)‐experienced patients.

[1]  M. Youle,et al.  Health economics in HIV disease. A review of the European literature. , 1999, PharmacoEconomics.

[2]  J. Knodel,et al.  The impact of the AIDS epidemic on older persons , 2002, AIDS.

[3]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[4]  M. Weinstein,et al.  Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. , 2005, The American journal of medicine.

[5]  S. Gingues,et al.  The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS‐defining cancers in Southern Alberta , 2006, HIV medicine.

[6]  M. Gill,et al.  The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[7]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[8]  The oncology impact of highly active antiretroviral therapy , 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[9]  B. Gazzard,et al.  The cost of antiretroviral drugs and influence on prescribing policies , 2006, International journal of STD & AIDS.

[10]  D. McCaffrey,et al.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.

[11]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[12]  Richard D Moore,et al.  Costs of HIV medical care in the era of highly active antiretroviral therapy. , 1999, AIDS.

[13]  M. Gill,et al.  The high cost of medical care for patients who present late (CD4<200 cells/μL) with HIV infection , 2004, HIV medicine.

[14]  Atlanta,et al.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[15]  R. Colebunders,et al.  Direct costs of health care for HIV/AIDS patients in Belgium , 2001, AIDS care.

[16]  Costing implications of recent treatment interruption studies. , 2006, AIDS.

[17]  T. Parikh,et al.  The High Cost of Medical Care , 2008 .

[18]  E. Tacconelli,et al.  Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario , 2003, AIDS.

[19]  M. Youle,et al.  Assessing the cost‐effectiveness of HAART for adults with HIV in England , 2001, HIV medicine.

[20]  Jerome H. Carter,et al.  Distribution of health care expenditures for HIV-infected patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Weinstein,et al.  Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  E. Beck,et al.  The cost of HIV treatment and care. A global review. , 2001, PharmacoEconomics.

[23]  E. Mokotoff,et al.  Characteristics of HIV infection in patients fifty years or older in Michigan. , 2001, AIDS patient care and STDs.

[24]  M. Gill,et al.  Longitudinal assessment (1995–2003) of hospitalizations of HIV‐infected patients within a geographical population in Canada , 2006, HIV medicine.

[25]  M. Suarez‐Almazor,et al.  Retention in care: a challenge to survival with HIV infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  A. Levy,et al.  The direct costs of HIV/AIDS care. , 2006, Lancet. Infectious Diseases (Print).

[27]  Richard D Moore,et al.  Treatment of HIV infection in the older patient , 2004, Expert review of anti-infective therapy.

[28]  Richard D Moore,et al.  Hospital and Outpatient Health Services Utilization Among HIV-Infected Adults in Care 2000–2002 , 2005, Medical care.

[29]  M. Gill,et al.  Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program , 2005 .

[30]  Milton C Weinstein,et al.  The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.

[31]  J. Graf von der Schulenburg,et al.  Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. , 2002, European journal of medical research.

[32]  Anke Richter,et al.  HIV Antiretroviral Treatment: Early Versus Later , 2005, Journal of acquired immune deficiency syndromes.

[33]  E. Beck,et al.  The cost-effectiveness of highly active antiretroviral therapy, Canada 1991–2001 , 2004, AIDS.